<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728127</url>
  </required_header>
  <id_info>
    <org_study_id>DICA-NUTS</org_study_id>
    <nct_id>NCT03728127</nct_id>
  </id_info>
  <brief_title>Brazilian Cardioprotective Diet and Nuts in Post-acute Myocardial Infarction</brief_title>
  <acronym>DICA-NUTS</acronym>
  <official_title>Effect of the Brazilian Cardioprotective Diet and Nuts on Cardiometabolic Parameters in Post-acute Myocardial Infarction: a Randomized Clinical Trial (DICA-NUTS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) is the leading cause of death worldwide. Dietary patterns and
      functional foods may play an important role in the management of cardiovascular risk factors
      such as overweight and dyslipidemia, as well as inflammation and oxidative stress. However,
      little is known regarding the effect of diets or specific nutrients on these parameters in
      individuals with acute myocardial infarction (AMI). The Brazilian Cardioprotective Diet
      (DicaBr) is based on Brazilian nutritional guidelines and also in a unique and ludic
      nutritional strategy. In a pilot study, this diet was effective in reducing blood pressure
      (intragroup comparison) and body weight (intergroup comparison) in individuals with
      established cardiovascular disease (CVD). However, the effectiveness of this dietary pattern
      supplemented with different kind of nuts is unknown. The aim of this study is to evaluate the
      effect of the DicaBr supplemented or not with 30g/day of different nuts on cardiometabolic
      parameters in patients with recent AMI. In this parallel randomized controlled trial, 500
      patients ≥40 years with a recent diagnosis of AMI (60 to 180 days) will be allocated to one
      of two study groups: 1) DicaBr group (DCB, control group); or 2) DicaBr group supplemented
      with mixed nuts (DCBN, intervention group). All patients will receive the same dietary
      prescription, the DCBN group also will receive 30g/day of nuts (10g of peanuts, 10g of cashew
      nuts and 10g of Brazilian nuts). A pilot study including 100 individuals who will receive
      only peanuts (30g/day) will be conducted. The primary outcome will be LDL-cholesterol (LDL-c)
      levels after 16 weeks. In the baseline and at the end of the study (16 weeks), lipid and
      glycemic profile and anthropometric indexes will be evaluated in both groups; inflammatory
      and oxidative stress markers, and adipokines will be evaluated in a subsample. It is expected
      that DicaBr supplemented with nuts will be superior to DicaBr alone to benefit patients with
      AMI regarding cardiometabolic parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-c</measure>
    <time_frame>Changes in LDL-c after 16 weeks</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-c), in mg/dL: LDL-c will be detected by Martins´mathematical formula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TC</measure>
    <time_frame>Changes in TC after 16 weeks</time_frame>
    <description>total cholesterol (TC), in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-c</measure>
    <time_frame>Changes in HDL-c after 16 weeks</time_frame>
    <description>high-density lipoprotein cholesterol (HDL-c), in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>Changes in TG after 16 weeks</time_frame>
    <description>Serum triglycerides (TG), in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-c</measure>
    <time_frame>Changes in VLDL after 16 weeks</time_frame>
    <description>Very low-density lipoprotein cholesterol (VLDL-c), in mg/dL; serum triglycerides, (in mg/dL) divided by 5 will be used to report VLDL-c in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NHDL-c</measure>
    <time_frame>Changes in NHDL-c after 16 weeks</time_frame>
    <description>non-HDL cholesterol (NHDL-c), in md/dL; total cholesterol (in mg/dL) and high-density lipoprotein cholesterol (in mg/dL) will be combined to report NHDL-c in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG/HDL-c</measure>
    <time_frame>Changes in TG/HDL-c after 16 weeks</time_frame>
    <description>TG/HDL-c ratio (TG/HDL-c), in mg/dL; serum triglycerides (in mg/dL) and high-density lipoprotein cholesterol (in mg/dL) will be combined to report TG/HDL-c in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Castelli I index</measure>
    <time_frame>Changes in Castelli I index after 16 weeks</time_frame>
    <description>TC/HDL-c ratio, in mg/dL; total cholesterol (in mg/dL) and high-density lipoprotein cholesterol (in mg/dL) will be combined to report Castelli I index in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Castelli II index</measure>
    <time_frame>Changes in Castelli II index after 16 weeks</time_frame>
    <description>LDL-c/HDL-c ratio, in mg/dL; low-density lipoprotein cholesterol (in mg/dL) and high-density lipoprotein cholesterol (in mg/dL) will be combined to report Castelli II index in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FG</measure>
    <time_frame>Changes in FG after 16 weeks</time_frame>
    <description>Fasting glucose (FG), in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>Changes in HbA1C after 16 weeks</time_frame>
    <description>glycated hemoglobin (HbA1C), in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INS</measure>
    <time_frame>Changes in INS after 16 weeks</time_frame>
    <description>Serum insulin (INS), in mU/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Changes in BMI after 16 weeks</time_frame>
    <description>Body mass index (BMI), in kg/m^2; weight (in kg) and height (in meters) will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WC</measure>
    <time_frame>Changes in WC after 16 weeks</time_frame>
    <description>Waist circumference (WC), in cm;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHR</measure>
    <time_frame>Changes in WHR after 16 weeks</time_frame>
    <description>Waist-to-hip ratio (WHR); waist circumference (in cm) and hip circumference (in cm) will be combined to report WHR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHt</measure>
    <time_frame>Changes in WHt after 16 weeks</time_frame>
    <description>Waist-to-height ratio (WHt); waist circumference (in cm) and height (in meters) will be combined to report WtH, in cm/m</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>DicaBr group and nuts (DCBN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DicaBr group (DCB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brazilian cardioprotective diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Brazilian cardioprotective diet</intervention_name>
    <description>Brazilian cardioprotective diet prescription</description>
    <arm_group_label>DicaBr group (DCB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Brazilian cardioprotective diet plus 30g/day of mixed nuts</intervention_name>
    <description>Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)</description>
    <arm_group_label>DicaBr group and nuts (DCBN)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients ≥ 40 years with previous AMI (60 to 180 days).

        Exclusion Criteria:

          -  Clinical indication of myocardial revascularization surgery (graf /bypass);

          -  HIV positive in treatment/AIDS;

          -  Chronic inflammatory diseases;

          -  Cancer;

          -  Chemical dependency/alcoholism;

          -  Chronic use of anti-inflammatories, anticonvulsants and immunosuppressive drugs;

          -  Pregnancy or lactation;

          -  Wheelchair users without conditions of anthropometric evaluation;

          -  Extreme obesity (BMI ≥40kg / m²);

          -  Use of dietary supplements;

          -  Rejection/allergy to oilseed consumption;

          -  Participation in other randomized studies at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Marcadenti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Cavalcanti, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardete Weber, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Bersh-Ferreira, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enilda Lara, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camila Torreglosa, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Machado, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucas Ribeiro, RD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline Marcadenti, PhD</last_name>
    <phone>(+55)11 30536611</phone>
    <phone_ext>3558</phone_ext>
    <email>amarcaden@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Cavalcanti, PhD</last_name>
    <phone>(+55)11 30536611</phone>
    <phone_ext>8201</phone_ext>
    <email>abiasi@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal do Rio Grande do Norte</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Paula Fayh, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia/Fundação Universitária de Cardiologia do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90620-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Marcadenti, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexandre Quadros, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Camila Weschenfelder, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Lorenzon, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Garofallo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas da Universidade Federal de Goiás (HC-UFG)</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Paula PF Carvalho, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Alagoas (UFAL)</name>
      <address>
        <city>Maceió</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra ML Vasconcelos, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul (HCPA-UFRGS)</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela C Souza, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Maranhão (UFMA)</name>
      <address>
        <city>São Luís</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José A Figueiredo Neto, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We intend to submit the Study Protocol as an article.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>July 2020</ipd_time_frame>
    <ipd_access_criteria>Will be available after publication.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

